This is why the also-ran pharma companies are so afraid that they will not be able to compete with this technology. This is why they pay think-tanks to find ways to slow down the advancement before the also-ran pharma become completely irrelevant. This is why the think tanks either dupe the ill informed to write their nonsense or pay the unethical to write their nonsense. There is a lot of money at stake in the old one drug for all, or the new drugs tailored by the patients own cells to create a drug better suited to that individual.